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a b s t r a c t
New derivatives of D-xylose with aglycons of the most efﬁcient glucose derived inhibitors of glycogen
phosphorylase were synthesized to explore the speciﬁcity of the enzyme towards the structure of the
sugar part of the molecules. Thus, 2-(b-D-xylopyranosyl)benzimidazole and 3-substituted-5-(b-D-xylo-
pyranosyl)-1,2,4-triazoles were obtained in multistep procedures from O-perbenzoylated b-D-xylopyr-
anosyl cyanide. Cycloadditions of nitrile-oxides and O-peracetylated exo-xylal obtained from the
pyranosyl cyanide furnished xylopyranosylidene-spiro-isoxazoline derivatives.
f O-peracetylated b-D-xylopyranosyl-thiohydroximates prepared from 1-thio-b-
ile-oxides gave xylopyranosylidene-spiro-oxathiazoles. The fully deprotected test
d against rabbit muscle glycogen phosphorylase b to show moderate inhibition
D-xylopyranosyl)-1,2,4-triazole (IC50 = 0.9 mM) only.







designed and synthesized 5-b-D-glucopyranosyl-3-substituted-
1,2,4-triazoles submicromolar inhibitors of GP (e.g., G) were
found.22,23 Best compounds in series of other types of anomeric
spirocycles like isoxazolines24 (e.g., H) and oxathiazoles25,26 (e.g.,
70I) showed inhibition approaching the low nanomolar range. To
explain the strong binding of these compounds extensive interac-
tions with the so-called b-channel of the enzyme were invoked
besides the ideal ﬁt of the sugar moiety in the catalytic site.12,13 Thus,
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The quest for inhibitors of glycogen phosphorylases (GPs) ha
been based on and fuelled by the potential application of suc
compounds as medication in type II diabetes mellitus1–3 and als
as possible therapeutic means in other diseased states like myocar
dial4,5 and cerebral6,7 ischemias and tumors.8–11
A large variety of compounds targeting one of the six bindin
3sites of GP (catalytic, inhibitor, allosteric, new allosteric, storage
and benzimidazole sites) have been developed to reach the nano-
molar range in their inhibitory efﬁciency.3,12 Catalytic site inhibitors
are almost exclusively glucose derivatives13 which have been
designed and studied following the observation that both anomeric
forms of D-glucose (A andB in Chart 1) aremodest inhibitors of GP.14
Early inhibitor design resulted in glucopyranosylidene-spiro-hyd-
antoinsC andDwith lowmicromolar inhibition constants.15,16Most
efﬁcient representatives of N-glucopyranosyl-1,2,3-triazoles17,18 E
and C-glucopyranosyl-benzimidazoles19–21 F proved similarly or
somewhat less effective than the hydantoins. Among the recently
the increasing binding strength must largely be attributed to the
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Please cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (Investigations into the speciﬁcity of GP towards various mono
saccharides revealed that changes in the sugar conﬁguration o
constitution resulted in a signiﬁcant decrease of the inhibition
for example, D-xylose (J) proved a 13–60-fold weaker inhibito
in comparison to the D-glucose anomers A and B.27 Since the efﬁ
ciency of the glucose derived inhibitors depended to a large exten
on the ﬁt of the aglycon in the b-channel, the D-xylo conﬁgure
analogues of the best inhibitors were time to time synthesize
 The b-channel of GPs is an empty space next to the active site in the direction
the b-substituent of the bound D-glucose surrounded by amino acid side chains
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Pld tested against GP to check if the interactions of the aglycon
ight overbalance the worse binding of the ‘truncated’ glycon.
to now xylopyranosylidene-spiro-hydantoins16 K and L as well
N-(b-D-xylopyranosyl)-1,2,3-triazoles (e.g., M) together with
ilar derivatives of 5-thio-xylose and the related cyclic sulfox-
es and sulfones28 were studied, however, showed no signiﬁcant
ect against RMGPb.
In this paper we report on the synthesis and enzymatic evalua-
n of xylose derived analogues N–Q of the best glucose based
hibitors of rabbit muscle glycogen phosphorylase b.
Results and discussion
For the preparation of the desired C-xylosyl benzimidazole N,
r recently published reaction sequence was applied.21 Thus,
,4-tri-O-benzoyl-b-D-xylopyranosyl cyanide29 (1, Scheme 1)
s hydrated to anhydro-aldonamide 2 which, on treatment by
3OBF4 gave ethyl imidate 3. Reaction of 3with 1,2-diamino-ben-
ne furnished the protected benzimidazole 4which was O-deben-























































































I Ar = 20



















1 R = CN
2 R = CONH2
(51 %)




4 R = Bz
(80 %)

















ease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (2014ructure elucidation of the compounds was straightforward by






















































80 oC 7 (91 %)









8 Ph 11 14 17
(68) (91) (91)
9 4-tBu-C6H4 12 15* 18
(42) (63) (77)
10 2-naphthyl 13 16 19
(52) (76) (90)
*NaOH, MeOH, Δ
14-16 R = H,
R' = Bn






eme 2. Synthesis of 3-(b-D-xylopyranosyl)-5-substituted-1,2,4-triazoles 17–19.sonances in the 13C spectra, due to fast proton exchange of the
o nitrogens, was observed similarly to earlier experiences.21
Next, to get an intermediate for the preparation of C-xylosyl-
,4-triazoles O, imidate 3 was reacted with tosylhydrazine,22,31
wever, instead of the expected N1-tosyl-(C-xylopyranosyl)form-
idrazone only its benzoic acid elimination product 6 could be
110lated.
Therefore, we turned to an alternative route23 (Scheme 2) and,
this end, 1 was transformed to tetrazole 7 by TMSN3–Bu2SnO.33
actions of 7 with non-puriﬁed N-benzyl-arenecarboximidoyl
The analogous O-peracetylated 5-(b-D-xylopyranosyl)tetrazole is known in the
32
), http://dx.doi.org/10.1016/j.carres.2014.05.020
chlorides obtained from the corresponding carboxamides 8–10 gave
the O-perbenzoylated N-benzyl-1,2,4-triazoles 11–13. These com-
pounds were ﬁrst O-deprotected by the Zemplén protocol30 or NaOH
in MeOH to give 14 and 16, as well as 15, respectively, followed by
catalytic hydrogenation to remove the N-benzyl protection to yield
the test compounds 17–19.
120 For the preparation of xylopyranosylidene-spiro-isoxazolines P,
O-peracetylated b-D-xylopyranosyl cyanide34 20 was transformed
to the corresponding anhydro-aldose tosylhydrazone 21 by apply-
ing our published method.35,36 Bamford–Stevens reaction37 of 21
was performed by thermal decomposition of the intermediate
salt35,38 to give exo-xylal 22 in excellent yield. 1,3-Dipolar cycload-
dition of 22 and nitrile-oxides,39 generated in situ by bleach
oxidation of the corresponding aromatic aldoximes,40 gave stere-
oselectively the protected spiro-isoxazolines 23–28, which were




























(10S) as the glucose-derived inhibitors I in Chart 1 were deacety-
lated under Zemplén conditions30 to obtain the test compounds
48 and 49.
Structural elucidation of the xylopyranosylidene-spiro-oxa-
170thiazoles 42–47 was based on comparisons of their NMR spectral
and optical rotation data to those of the D-gluco counterparts where
at least for one compound (I Ar = Ph in Chart 1) the structure was
determined by X-ray crystallography.44 For 42–47 the presence of
a xylopyranose ring in the 4C1 conformation was deduced from the
vicinal coupling constants in the 1H NMR spectra. To establish the
conﬁguration of the spiro centre, characteristic differences
observed for the 10R and 10S epimers of the D-gluco derivatives
(Table 1, 50, 51 and 52, 53, respectively) were sought for in the
data of the D-xylo compounds. Thus, for the D-gluco conﬁgured epi-
180meric pairs 50, 51, and 52, 53 the change of the spiro conﬁguration
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by Nuclear Overhauser Effect (NOE) difference spectra showin
spatial vicinity of the isoxazoline methylene protons with H-2
(but not with H-30 and H-50) of the sugar ring. Similar exclusive ste
reoselectivity was observed in the formation of the glucose
derived isoxazolines24 (Chart 1, H) (Scheme 3).
Synthesis of the xylopyranosylidene-spiro-oxathiazoles Q wa
started by the conversion of O-peracetylated 1-thio-b-D-xylopyra
nose41 35 to S-b-D-xylopyranosyl thiohydroximates 36–3
(Scheme 4). One of the generally applied methods to get S-glycosy
thiohydroximates42 is the reaction of the corresponding 1-thio
sugars with nitrile-oxides. In addition to the above mentioned ox
dative processes, a frequently used way to obtain nitrile-oxide
in situ is the base-induced dehydrohalogenation of hydroximoy
halides which are isolable after halogenation (by e.g., Cl2, NCS o
NBS) of aldoximes.39 Because of the sensitivity of thiols to oxida
tion, nitrile oxides were generated from hydroximoyl chloride
by Et3N (method a in Scheme 4) in the presence of 35. A recentl
reported procedure to perform the chlorination and HCl elimina
tion in one continuous operation (method b), suggested to be supe
rior especially for the preparation of glycosyl thiohydroximates,4
was also studied. Although both methods gave good yields of th
expected products 36–38, in our hands the conventional dehydro
chlorination of the isolated hydroximoyl chlorides gave bette
results (compare yields for methods a and b in Scheme 4). Thiohy
droximates 36–38 were deacetylated by the Zemplén method30 t
give the test compounds 39–41.
5Ring closure of the thiohydroximates was effected by NBS under
irradiation as reported for the preparation of several glycoenzyme
inhibitors of this spiro-oxathiazole type.26,44,45 Expectedly, the for-
mation of two spiro epimers was observed, however, in contrast to
earlier ﬁndings with hexopyranose derived compounds where the
anomeric conﬁguration of the thiohydroximate was retained in the
major cyclized product, in these reactions compounds of the
inverted conﬁguration 42–44 were isolated as the main products.
















Ar Ph 4-tBu-C6H4 4-CF3-C6H4 1-naphthyl 2-napht
Yield 23 24 25 26 27
(%) (74) (67) (57) (60) (44)
29 30 31 32 33
(90) (98) (91) (79) (85)
Scheme 3. Synthesis of D-xylopyra
Please cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (H-40 protons, but H-30 and H-50 showed 0.5 and 0.3 ppm differ
ence, respectively, depending on the presence of an axial S versus
atom in the spiro-heterocycle. The same tendency was also presen
in the chemical shift values of the respective protons of the D-xy
derivatives 42–44 versus 45–47. The chemical shifts for the spir
carbons were consistently higher for the 10R than for the 1
compounds in both series. Finally, the 10R derivatives were signi
icantly more dextrorotatory than the 10S compounds. The spir
conﬁgurations were assigned by utilizing these coincidences.
Enzymatic evaluation of the deprotected compounds agains
rabbit muscle glycogen phosphorylase b (RMGPb) was carried ou
as described before.16 All but one of the deprotected xylose deriv
atives had no inhibition at 625 lM concentration. The onl
compound of the series having a moderate effect was 3-(2-naph
thyl)-5-(b-D-xylopyranosyl)-1,2,4-triazole (19) with an IC50 valu
of 900 lM (calculated46 Ki = 491 lM). This inhibition is more tha
three orders of magnitude weaker than that of the D-gluco counter
part (G in Chart 1, Ki = 0.41 lM). However, a comparison of th
ratio of inhibitor constants for the xylo/gluco hydantoins (Chart 1
compounds K/C 2800–3800), thiohydantoins (Chart 1, com
pounds L/D 2300) and 3-(2-naphthyl)-1,2,4-triazoles (Chart 1
compounds O(=19)/G 1200) shows a clear tendency in makin
the binding stronger by the aglycons which ﬁt better in the b-chan
nel. Although the ﬁndings reveal that the aglycons in these xylos
derived compounds (provided that they indeed bind to the cata
lytic site of GP) still have no strong enough interactions to full
overcompensate the loss of the CH2OH side chain of the sugar mo
ety, the above tendency may foreshadow much more efﬁcient
210xylose-derived inhibitors of GP.
In conclusion, new C-xylopyranosyl benzimidazole and 1,2,4-
triazoles as well as xylopyranosylidene-spiro-isoxazolines and -
oxathiazoles were prepared by adapting procedures used for the
syntheses of analogous glucose-derived inhibitors of glycogen
phosphorylase. Evaluation of the compounds as inhibitors of rabbit
muscle glycogen phosphorylase b showed very weak inhibition for
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Plher compounds proved ineffective in a concentration of 625 lM.
ese observations show that the aglycons rendering their glucose
rivatives to nanomolar inhibitors, are not yet capable to com-
etely override the effect of losing the side chain of the glucose
oiety. Nevertheless, the increase in the binding strength of the
lose derivatives with the more efﬁcient aglycons may predict
ongly binding inhibitors derived from sugars other than glucose.
Experimental
. General methods
Melting points were measured on a Koﬂer hot-stage and are
corrected. Optical rotations were determined with a Perkin-
er 241 polarimeter at rt. NMR spectra were recorded with a
uker 360 (360/90 MHz for 1H/13C) spectrometer. Chemical shifts
e referenced to Me4Si (1H), or to the residual solvent signals (13C).
icroanalyses were performed on an Elementar Vario Micro cube
strument. ESI-MS spectra were measured with a Thermo Scien-
c LTQ XL spectrometer. TLC was performed on DC-Alurolle
eselgel 60 F254 (Merck) plates, visualized under UV light and by
ntle heating. For column chromatography Kieselgel 60 (Merck,
rticle size 0.063–0.200 mm) was used. CH2Cl2, CHCl3, toluene
dm-xylene were distilled from P4O10 and stored over 4 Å molec-
ar sieves or sodium wires. MeOH was puriﬁed by distillation



































Scheme 4. Synthesis of D-xylopyrano
le 1


























H-20 5.52 5.58 5.56 5.60 5.66
H-30 5.13 5.15 5.17 5.10 5.13
H-40 5.07 5.10 5.11 5.27 5.29
H-50ax 3.79 3.85 3.83 4.10 4.18
H-50eq 4.19 4.28 4.22 — —
C-10 126.6 125.8 126.7 127.3 126.3
[a]D +178 +151 +182 +179 +99
ata taken from Ref. 44.ease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (2014d iodine. 1,4-Dioxane was distilled from sodium benzophenone
tyl and stored over sodium wires. 2,3,4-Tri-O-benzoyl-b-D-xylo-
ranosyl cyanide29 (1), N-benzyl-arenecarboxamides23 (8–10),
,4-tri-O-acetyl-b-D-xylopyranosyl-cyanide34 (20), 2,3,4-tri-O-
etyl-1-thio-b-D-xylopyranose41 (35), arenecarbaldoximes47 and
hydroxy-arenecarboximidoyl chlorides47 were synthesized
cording to published procedures.
. General procedure I for the Zemplén-deacylation30
An O-acylated compound was dissolved in anhydrous MeOH
mL/100 mg, a few drops of CHCl3 were added in case of incom-
ete dissolution) and a catalytic amount of a NaOMe solution
1 M in MeOH) was added. The mixture was kept at rt and
onitored by TLC (7:3 CHCl3–MeOH). After disappearance of the
rting material the mixture was neutralized with a cation
change resin Amberlyst 15 (H+ form), then the resin was ﬁltered
f and the solvent removed. The residue was puriﬁed either by
lumn chromatography or by crystallization.
. General procedure II for the synthesis of 4-benzyl-3-(20,30,40-
-O-benzoyl-b-D-xylopyranosyl)-5-substituted-1,2,4-triazoles
1–13)
An N-benzyl-arenecarboxamide23 (8–10, 4.63 mmol, 3 equiv)











Ar Ph 1-naphthyl 2-naphthyl
36 37 38
a) (63) (83) (91)

































5.56 5.59 5.60 5.63 5.67
5.62 5.68 5.66 5.63 5.67
5.12 5.14 5.15 5.27 5.29
4.04 4.11 4.07 4.42 4.51
4.00 4.06 4.02 — —
122.6 121.9 122.6 122.4 121.8
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(20 mL) was evaporated from the residue. 5-(2,3,4-Tri-O-benzoy
b-D-xylopyranosyl)tetrazole (7, 1.54 mmol, 1 equiv) and anhydrou
toluene or m-xylene (20 mL) were added, the mixture was heate
to reﬂux temperature and the reaction was monitored by TLC (1:
EtOAc–hexane). After total consumption of the tetrazole the so
vent was removed and the residue was puriﬁed by colum
chromatography.
3.4. General procedure III for the removal of benzyl protectin
groups
A benzylated compound (0.5 mmol) was dissolved in anhydrou
MeOH (25 mL), 10% Pd(C) (20 mg) was added and H2 gas was bub
bled through the reaction mixture at 50 C. After disappearance o
the starting material (monitored by TLC, 7:3 CHCl3–MeOH) th
reaction mixture was ﬁltered through a pad of Celite, the solven
was evaporated and the residue was puriﬁed by colum
chromatography.




(22, 100 mg, 0.37 mmol) and an arenecarbaldoxime (1.85 mmo
5 equiv) were dissolved in THF (4.8 mL) under N2 atmosphere. T
this stirred solution domestic bleach (5% available chlorin
3.86 mL) was added with a syringe pump in 5 h at rt. The reactio
was stirred for additional 24 h. After complete disappearance o
the starting exo-xylal (TLC, 1:1 EtOAc–hexane) the reaction wa
diluted with EtOAc (20 mL), the phases were separated and th
organic layer was washed with water (3  15 mL), dried ove
MgSO4 and the solvent was evaporated under reduced pressur
The residue was puriﬁed by column chromatography (1:3 EtOAc
hexane).




1 mmol) and the corresponding N-hydroxy-arenecarboximidoy
chloride (1.5 mmol) were dissolved in anhydrous CH2Cl2 (10 mL
Et3N was added (3 mmol) and the reaction mixture was stirred a
rt under Ar. After completion of the reaction (1.5 h, monitored b
TLC, 1:2 EtOAc–hexane) the mixture was treated with 2 M HC
solution (20 mL), then the separated organic phase was washe
with water (2  20 mL). The organic layer was dried over MgSO
ﬁltered and evaporated. The residue was puriﬁed by column chro
matography (1:2 EtOAc–hexane) to give an oil that was crysta
lized from hexane.
3.7. General procedure VI (method b)43 for the synthesis of
2,3,4-tri-O-acetyl-1-S-(Z)-arylhydroximoyl-1-thio-b-D-xylopyra
noses (36–38)
An arenecarbaldoxime (1.5 mmol) was dissolved in CH2C
(10 mL) and the solution was extracted with domestic bleach (5
available chlorine, 5 mL). After drying over MgSO4 the organ
phase was added dropwise to a solution of 2,3,4-tri-O-acetyl-1
thio-b-D-xylopyranose41 (35, 0.29 g, 1 mmol) in CH2Cl2 (10 mL
After addition of Et3N (3 mmol) the reaction mixture was stirre
at rt under Ar, and monitored by TLC (1:2 EtOAc–hexane). Whe
the starting material was consumed (1.5 h) the mixture was trea
ted with 2 M HCl solution (20 mL), then the separated organPlease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (phase was washed with water (2  20 mL). The organic layer wa
dried over MgSO4, ﬁltered and evaporated. The residue was pur
ﬁed by column chromatography (1:2 EtOAc–hexane) to give a
oil that was crystallized from hexane.




pyranose (36–38, 1 mmol) and NBS (1.2 mmol) were dissolved i
anhydrous CHCl3 (20 mL) and the mixture was boiled and illum
nated by a 250 W heat lamp. When TLC (1:2 EtOAc–hexane
showed total consumption of the starting material (1 h) the reac
tion mixture was diluted with CHCl3 (30 mL), extracted with sat
aq Na2S2O4 solution (40 mL), satd aq NaHCO3 solution (40 mL
and water (40 mL). The organic layer was dried over MgSO4, ﬁ
tered and evaporated under reduced pressure. The residue wa
puriﬁed by column chromatography.
3.9. Synthesis and characterization of the compounds
3.9.1. C-(2,3,4-Tri-O-benzoyl-b-D-xylopyranosyl)formamide (2)
2,3,4-Tri-O-benzoyl-b-D-xylopyranosyl cyanide29 (1, 3.0
6.4 mmol) was suspended in a solution of HBr in AcOH (8 m
33% m/m) and the mixture was stirred at rt. After disappearanc
of the starting material (3 h, monitored by TLC, 1:1 EtOAc–hexane
the reaction mixture was poured into ice-water (40 mL) an
extracted with CHCl3 (2  30 mL). The combined organic phase
were washed with satd aq NaHCO3 solution (2  30 mL), then wit
water (30 mL), dried over MgSO4, ﬁltered and the solvent wa
removed. The remaining oil was crystallized from Et2O to giv
1.58 g (51%) of 2 as a white solid. Mp: 173–175 C; [a]D 15 (
0.5, DMSO); 1H NMR (DMSO-d6) d (ppm): 7.88–7.38 (17H, m, A
CONH2), 5.89, 5.63 (2  1H, 2 pseudo t, J = 9.2, 9.2 Hz in each, H
2, H-3), 5.40 (1H, ddd, J = 10.5, 9.2, 5.5 Hz, H-4), 4.35–4.32 (2H
m, H-1, H-5eq), 3.90 (1H, pseudo t, J = 11.2, 10.5 Hz, H-5ax); 13
NMR (DMSO-d6) d (ppm): 168.7 (CONH2), 165.1, 164.8, 164.
(C@O), 133.7–128.6 (Ar), 76.7, 73.2, 70.0, 69.3 (C-1–C-4), 65.3 (C
5). Anal. Calcd for C27H23NO8 (489.47): C, 66.25; H, 4.74; N, 2.86




2.04 mmol) and Et3OBF4 (1.16 g, 6.13 mmol, 3 equiv) were stirre
in anhydrous CH2Cl2 (15 mL) at rt under Ar, and monitored by TL
(1:1 EtOAc–hexane). After completion of the reaction (24 h), th
mixture was diluted with CH2Cl2 (50 mL), extracted with satd a
NaHCO3 solution (40 mL) and then with water (40 mL). The organ
phase was dried over MgSO4, ﬁltered and the solvent was remove
under diminished pressure. The pale yellow amorphous crud
product (1.02 g, 96%) was used without further puriﬁcation. R
0.59 (1:1 EtOAc–hexane); 1H NMR (CDCl3) d (ppm): 8.00–7.2
(16H, m, Ar, NH), 6.00, 5.59 (2  1H, 2 pseudo t, J = 9.2, 9.2 Hz i
each, H-2, H-3), 5.46 (1H, ddd, J = 10.6, 9.2, 5.3 Hz, H-4), 4.5
(1H, dd, J = 11.2, 5.3 Hz, H-5eq), 4.14 (1H, d, J = 9.2 Hz, H-1
4.12–3.92 (2H, m, CH2), 3.71 (1H, pseudo t, J = 11.2, 10.6 Hz, H
5ax), 0.86 (3H, t, 7.3 Hz, CH3); 13C NMR (CDCl3) d (ppm): 167.5
165.4, 165.1, 164.9 (C@O, C@NH), 133.2–128.0 (Ar), 75.1, 72.6
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Plre heated in anhydrous CH2Cl2 (3 mL) at reﬂux temperature, and
e reaction was monitored by TLC (1:1 EtOAc–hexane). After
mpletion of the reaction (5 h) the solvent was evaporated, and
e residue was puriﬁed by column chromatography (2:3 EtOAc–
xane) to give 0.13 g (80%) pale yellow solid. Mp: 123–125 C;
]D 96 (c 0.5, CHCl3); 1H NMR (CDCl3) d (ppm): 11.17 (1H, br s,
), 7.97–7.17 (19H, m, Ar), 6.06, 5.85 (2  1H, 2 pseudo t,
9.4, 9.4 Hz in each, H-20, H-30), 5.42 (1H, ddd, J = 9.8, 9.4,
Hz, H-40), 5.17 (1H, d, J = 9.4 Hz, H-10), 4.42 (1H, dd, J = 11.3,
Hz, H-50eq), 3.76 (1H, pseudo t, J = 11.3, 9.8 Hz, H-50ax); 13C
R (CDCl3) d (ppm): 165.6, 165.4, 165.3 (C@O), 149.1 (C-2),
8.3 (C-3a, C-7a), 133.3–128.1 (Ar), 122.7 (C-5, C-6), 115.5 (C-4,
7), 75.4, 73.2, 71.4, 69.7 (C-10–C-40), 67.0 (C-50). Anal. Calcd for
3H26N2O7 (562.57): C, 70.45; H, 4.66; N, 4.98. Found: C, 70.51;
4.80; N, 4.76.
.4. 2-(b-D-Xylopyranosyl)-benzimidazole (5)
From compound 4 (0.22 g, 0.39 mmol) according to General
ocedure I (Section 3.2). Reaction time: 1.5 h. Puriﬁed by column
romatography (85:15 CHCl3–MeOH) to yield 79 mg (81%) white
orphous solid. Rf: 0.45 (7:3 CHCl3–MeOH); [a]D 18 (c 0.5,
SO); 1H NMR (DMSO-d6) d (ppm): 12.53 (1H, s, NH), 7.56–7.48
H, m, benzimidazole), 7.17–7.16 (2H, m, benzimidazole), 5.21–
4 (3H, m, 3  OH), 4.31 (1H, d, J = 9.2 Hz, H-10), 3.87 (1H, dd,
11.2, 5.3 Hz, H-50eq), 3.64 (1H, pseudo t, J = 9.2, 9.2 Hz, H-20 or
30), 3.47 (1H, ddd, J = 10.6, 9.2, 5.3 Hz, H-40), 3.31 (1H, pseudo t,
9.2, 9.2 Hz, H-20 or H-30), 3.26 (1H, pseudo t, J = 11.2, 10.6 Hz,
50ax); 13C NMR (DMSO-d6) d (ppm): 152.4 (C-2), 142.5, 134.1
-3a, C-7a), 122.1, 121.1, 118.7, 111.3 (C-4–C-7), 78.0, 76.9, 72.8,
.2 (C-10–C-40), 69.6 (C-50). Anal. Calcd for C12H14N2O4 (250.25):




9 g, 0.76 mmol) and p-toluenesulfonylhydrazide (0.21 g,
3 mmol, 1.5 equiv) were dissolved in anhydrous CH2Cl2
2 mL), stirred at rt and monitored by TLC (1:1 EtOAc–hexane).
ter completion of the reaction (3 days) the solvent was evapo-
ted, and the residue was puriﬁed by column chromatography
:7 EtOAc–hexane). The resulting pale yellow oil was crystallized
m Et2O to give 0.11 g (27%) white solid. Mp: 120–121 C; [a]D
20 (c 0.5, CHCl3); 1H NMR (CDCl3) d (ppm): 8.01–7.28 (14H,
, Ar), 5.97, 5.58–5–35 (5H, 3 br signals, H-2, H-3, H-4, NH2),
4, 4.26 (2  1H, 2 br signals, H-5eq, H-5ax), 2.37 (3H, s, CH3);
NMR (CDCl3) d (ppm): 165.3, 165.0 (C@O), 154.5, 148.2,
4.1 (C-1, C@N, Ts-C-1) 134.5-128.3 (Ar), 97.9 (C-2), 67.2 (C-3
C-4), 65.0 (C-5), 63.9 (C-3 or C-4), 21.5 (CH3). MS-ESI (m/z): calcd
r C27H26N3O7S+ [M+H]+: 536.15. Found: 536.42.
.6. 5-(20,30,40-Tri-O-benzoyl-b-D-xylopyranosyl)tetrazole (7)
2,3,4-Tri-O-benzoyl-b-D-xylopyranosyl cyanide29 (1, 2.00 g,
4 mmol), TMSN3 (2.23 mL, 16.96 mmol) and Bu2SnO (0.10 g,
2 mmol) were dissolved in anhydrous toluene (60 mL) and
ated at 80 C overnight. Toluene was then removed under
duced pressure, and the residue was crystallized from MeOH to
ld 1.98 g (91%) white solid. Mp: 176–177 C; [a]D 29 (c 1.02,
Cl3); 1H NMR (CDCl3) d (ppm): 14.73 (1H, br s, NH), 7.99–7.19
5H, m, Ar), 6.08, 5.87 (2  1H, 2 pseudo t, J = 9.5, 9.4 Hz in each,
20, H-30), 5.61 (1H, ddd, J = 10.8, 9.7, 5.7 Hz, H-40), 5.26 (1H, d,
9.6 Hz, H-10), 4.56 (1H, dd, J = 11.3, 5.3 Hz, H-50eq), 3.80 (1H,
eudo t, J = 11.3, 10.8 Hz, H-50ax); 13C NMR (CDCl3) d (ppm):
5.9, 165.8, 165.5 (C@O), 152.3 (tetrazole C-5), 133.7-128.3 (Ar),
.9, 72.2, 71.1, 69.7 (C-10–C-40), 67.4 (C-50). Anal. Calcd for
7H22N4O7 (514.49): C, 63.03; H, 4.31; N, 10.89. Found: C, 62.99;
4.29; N, 10.90.ease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (2014.7. 4-Benzyl-3-phenyl-5-(20,30,40-tri-O-benzoyl-b-D-
lopyranosyl)-1,2,4-triazole (11)
From tetrazole 7 (0.70 g, 1.36 mmol) and N-benzyl-benzamide
, 0.86 g, 4.08 mmol) in toluene according to General procedure
(Section 3.3). Reaction time: 16 h. Puriﬁed by column chroma-
graphy (1:1 EtOAc–hexane) to yield 0.65 g (68%) white crystals.
p: 230–231 C; [a]D 33 (c 0.50, CHCl3); 1H NMR (CDCl3) d
pm): 7.96–7.05 (25H, m, Ar), 6.02, 5.92 (2  1H, 2 pseudo t,
9.4, 9.5 Hz in each, H-20, H-30), 5.49 (1H, d, J = 16.3 Hz, PhCH2),
1 (1H, ddd, J = 9.8, 9.4, 5.3 Hz, H-40), 5.33 (1H, d, J = 16.3 Hz,
CH2), 4.94 (1H, d, J = 9.6 Hz, H-10), 4.46 (1H, dd, J = 11.1, 5.3 Hz,
50eq), 3.60 (1H, pseudo t, J = 11.1, 10.7 Hz, H-50ax); 13C NMR
DCl3) d (ppm): 165.7, 165.4, 164.6 (C@O), 156.4, 150.2 (triazole
3, C-5), 135.3–126.3 (Ar), 73.3, 73.3, 69.8, 69.7 (C-10–C-40), 67.2
-50), 48.0 (PhCH2). Anal. Calcd for C41H33N3O7 (679.72): C,
.45; H, 4.89; N, 6.18. Found: C, 72.56; H, 4.94; N, 6.12.
.8. 4-Benzyl-3-(4-tert-butylphenyl)-5-(20,30,40-tri-O-benzoyl-
D-xylopyranosyl)-1,2,4-triazole (12)
From tetrazole 7 (1.00 g, 1.94 mmol) and N-benzyl-4-tert-
tylbenzamide (9, 1.56 g, 5.83 mmol) in m-xylene according to
neral procedure II (Section 3.3). Reaction time: 4 h. Puriﬁed by
lumn chromatography (2:3 EtOAc–hexane) to yield 0.60 g
2%) white crystals. Mp: 234–236 C; [a]D 18 (c 0.52, CHCl3);
NMR (CDCl3) d (ppm): 7.96–7.07 (24H, m, Ar), 6.00, 5.90
 1H, 2 pseudo t, J = 9.4 Hz in each, H-20, H-30), 5.47 (1H, d,
16.5 Hz, PhCH2), 5.41–5.33 (2H, m, H-40, PhCH2), 4.89 (1H, d,
9.7 Hz, H-10), 4.44 (1H, dd, J = 11.2, 5.1 Hz, H-50eq), 3.57 (1H,
eudo t, J = 11.2, 10.7 Hz, H-50ax), 1.30 (9H, s, C(CH3)3); 13C NMR
DCl3) d (ppm): 165.8, 165.4, 164.5 (C@O), 156.5, 153.4 (triazole
3, C-5), 150.0, 135.5–123.7 (Ar), 73.4, 73.2, 69.8, 69.7 (C-10–C-
, 67.2 (C-50), 48.0 (PhCH2), 34.8 (C(CH3)3), 31.1 (C(CH3)3). Anal.
lcd for C45H41N3O7 (735.82): C, 73.45; H, 5.62; N, 5.71. Found:
73.50; H, 5.59; N, 5.67.
.9. 4-Benzyl-3-(2-naphthyl)-5-(20,30,40-tri-O-benzoyl-b-D-
lopyranosyl)-1,2,4-triazole (13)
From tetrazole 7 (1.00 g, 1.94 mmol) and N-benzyl-naphtha-
e-2-carboxamide (10, 1.52 g, 5.82 mmol) in m-xylene according
General procedure II (Section 3.3). Reaction time: 3 h. Puriﬁed
column chromatography (1:1 EtOAc–hexane) to yield 0.73 g
2%) white crystals. Mp: 226–227 C; [a]D 39 (c 0.47, CHCl3);
NMR (CDCl3) d (ppm): 7.97–7.08 (27H, m, Ar), 6.04, 5.95
 1H, 2 pseudo t, J = 9.5, 9.4 Hz in each, H-20, H-30), 5.55 (1H,
J = 16.4 Hz, PhCH2), 5.45–5.38 (2H, m, H-40, PhCH2), 5.00 (1H,
J = 9.6 Hz, H-10), 4.47 (1H, dd, J = 11.2, 5.3 Hz, H-50eq), 3.62
H, pseudo t, J = 11.2, 10.7 Hz, H-50ax); 13C NMR (CDCl3) d
pm): 165.7, 165.4, 164.7 (C@O), 156.5, 150.3 (triazole C-3, C-5),
5.3–123.8 (Ar), 73.3, 73.2, 69.9, 69.7 (C-10–C-40), 67.2 (C-50),
.2 (PhCH2). Anal. Calcd for C45H35N3O7 (729.78): C, 74.06; H,
3; N, 5.76. Found: C, 74.11; H, 4.85; N, 5.72.
.10. 4-Benzyl-3-phenyl-5-(b-D-xylopyranosyl)-1,2,4-triazole
4)
From compound 11 (0.44 g, 0.63 mmol) according to General
ocedure I (Section 3.2). Reaction time: 4 h. Puriﬁed by column
romatography (9:1 CHCl3–MeOH) to yield 0.21 g (91%) white
orphous solid. Rf: 0.46 (4:1 CHCl3–MeOH); [a]D 15 (c 0.50,
SO); 1H NMR (DMSO-d6) d (ppm): 7.49–7.41 (5H, m, Ar),
3–7.22 (3H, m, Ar), 6.94 (2H, d, J = 6.3 Hz, Ar), 5.38 (1H, d,
19.2 Hz, PhCH2), 5.32 (1H, d, J = 18.2 Hz, PhCH2), 4.31 (1H, d,
9.6 Hz, H-10), 3.86 (1H, pseudo t, J = 9.1, 8.9 Hz, H-20 or H-30),
3 (1H, dd, J = 10.7, 5.8 Hz, H-50eq), 3.43 (1H, ddd, J = 10.6, 9.4,
Hz, H-40), 3.26 (1H, pseudo t, J = 9.1, 8.7 Hz, H-20 or H-30),
6 (1H, pseudo t, J = 10.7, 10.6 Hz, H-50ax); 13C NMR (DMSO-d6)
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10 June 2014128.8, 128.7, 127.9, 127.3, 126.5 (Ar), 78.1, 73.3, 71.8, 69.5 (C-10–C
40), 70.2 (C-50), 47.0 (PhCH2). Anal. Calcd for C20H21N3O4 (367.40
C, 65.38; H, 5.76; N, 11.44. Found: C, 65.30; H, 5.78; N, 11.45.
3.9.11. 4-Benzyl-3-(4-tert-butylphenyl)-5-(b-D-xylopyranosyl)-
1,2,4-triazole (15)
Triazole 12 (0.53 g, 0.63 mmol) was dissolved in anhydrou
MeOH (4 mL), 1 M NaOH/MeOH (3 mL) was added and the mixtur
was reﬂuxed for 1 h. The excess of NaOH was neutralized by AcOH
After evaporation the crude product was puriﬁed by column chro
matography (9:1 CHCl3–MeOH) to yield 0.19 g (63%) white amor
phous solid. Rf: 0.56 (4:1 CHCl3–MeOH); [a]D 15.0 (c 0.5
DMSO); 1H NMR (DMSO-d6) d (ppm): 7.42 (4H, m, Ar), 7.26–7.2
(3H, m, Ar), 6.96 (2H, d, J = 6.5 Hz, Ar), 5.37 (1H, d, J = 18.1 H
PhCH2), 5.32 (1H, d, J = 17.8 Hz, PhCH2), 4.23 (1H, d, J = 9.6 Hz, H
10), 3.83 (1H, pseudo t, J = 9.1, 9.0 Hz, H-20 or H-30), 3.72 (1H, dd
J = 10.6, 4.7 Hz, H-50eq), 3.40 (1H, ddd, J = 10.6, 9.1, 4.7 Hz, H-40
3.21 (1H, pseudo t, J = 8.7, 8.7 Hz, H-20 or H-30), 3.12 (1H, pseud
t, J = 10.7, 10.6 Hz, H-50ax), 1.25 (9H, s, C(CH3)3); 13C NM
(DMSO-d6) d (ppm): 154.6, 153.3 (triazole C-3, C-5), 152.8, 136.2
128.8, 128.4, 127.8, 126.3, 125.8, 124.4 (Ar), 78.0, 73.3, 71.7, 69.
(C-10–C-40), 70.1 (C-50), 46.8 (PhCH2), 34.7 (C(CH3)3), 31.
(C(CH3)3). Anal. Calcd for C24H29N3O4 (423.50): C, 68.06; H, 6.90
N, 9.92. Found: 68.19; H, 6.92; N, 9.91.
3.9.12. 4-Benzyl-3-(2-naphthyl)-5-(b-D-xylopyranosyl)-1,2,4-
triazole (16)
From compound 13 (0.34 g, 0.47 mmol) according to Genera
procedure I (Section 3.2). Reaction time: 3 h. Puriﬁed by colum
chromatography (9:1 CHCl3–MeOH) to yield 0.15 g (76%) whit
amorphous solid. Rf: 0.40 (4:1 CHCl3–MeOH); [a]D 14 (c 0.5
DMSO); 1H NMR (DMSO-d6) d (ppm): 8.04–6.97 (12H, m Ar), 5.4
(1H, d, J = 18.3 Hz, PhCH2), 5.44 (1H, d, J = 18.3 Hz, PhCH2), 4.3
(1H, d, J = 9.6 Hz, H-10), 3.91 (1H, pseudo t, J = 9.1, 9.0 Hz, H-20 o
H-30), 3.78 (1H, dd, J = 10.7, 4.8 Hz, H-50eq), 3.45 (1H, ddd, J = 9.6
9.0, 5.1 Hz, H-40), 3.29 (1H, pseudo t, J = 8.8, 8.7 Hz, H-20 or H-30
3.13 (1H, pseudo t, J = 10.8, 10.8 Hz, H-50ax); 13C NMR (DMSO-d
d (ppm): 154.7, 153.8 (triazole C-3, C-5), 136.3–124.7 (Ar), 78.1
73.4, 71.8, 69.5 (C-10–C-40), 70.2 (C-50), 47.2 (PhCH2). Anal. Calc
for C24H23N3O4 (417.46): C, 69.05; H, 5.55; N, 10.07. Found: C
68.99; H, 5.49; N, 10.12.
3.9.13. 3-Phenyl-5-(b-D-xylopyranosyl)-1,2,4-triazole (17)
From compound 14 (0.20 g, 0.54 mmol) according to Genera
procedure III (Section 3.4). Reaction time: 2 h. Puriﬁed by colum
chromatography (9:1 CHCl3–MeOH) to yield 0.14 g (91%) whit
amorphous solid. Rf: 0.30 (4:1 CHCl3–MeOH); [a]D 24 (c 0.48
MeOH); 1H NMR (CD3OD) d (ppm): 7.90 (2H, br s, Ar), 7.40 (3H
m, Ar), 4.37 (1H, d, J = 9.6 Hz, H-10), 4.00 (1H, dd, J = 11.1, 5.3 H
H-50eq), 3.80 (1H, br s, H-20 or H-30), 3.68 (1H, ddd, J = 10.1, 9.
5.3 Hz, H-40), 3.49 (1H, pseudo t, J = 9.0, 9.0 Hz, H-20 or H-30), 3.3
(1H, pseudo t, J = 11.1, 10.8 Hz, H-50ax); 13C NMR (CD3OD)
(ppm): 163.0, 156.9 (triazole C-3, C-5), 131.1, 129.9, 127.5 (Ar
79.5, 77.2, 74.2, 71.1 (C-10–C-40), 71.5 (C-50). Anal. Calcd fo
C13H15N3O4 (277.28): C, 56.31; H, 5.45; N, 15.15. Found: C, 56.43
H, 5.49; N, 15.07.
3.9.14. 3-(4-tert-Butylphenyl)-5-(b-D-xylopyranosyl)-1,2,4-
triazole (18)
From compound 15 (0.18 g, 0.43 mmol) according to Genera
procedure III (Section 3.4). Reaction time: 2 h. Puriﬁed by colum
chromatography (9:1 CHCl3–MeOH) to yield 0.11 g (77%) whit
amorphous solid. Rf: 0.43 (4:1 CHCl3–MeOH); [a]D 24 (c 0.49
MeOH); 1H NMR (CD3OD) d (ppm): 7.88 (2H, d, J = 8.2 Hz, Ar
7.47 (2H, d, J = 8.2 Hz, Ar), 4.38 (1H, d, J = 9.7 Hz, H-10), 4.01 (1H
dd, J = 11.1, 5.3 Hz, H-50eq), 3.83 (1H, pseudo t, J = 8.6, 8.3 HPlease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (H-20 or H-30), 3.68 (1H, ddd, J = 10.0, 9.2, 5.3 Hz, H-40), 3.50 (1H
pseudo t, J = 9.0, 9.0 Hz, H-20 or H-30), 3.37 (1H, pseudo t, J = 11.1
10.0 Hz, H-50ax), 1.29 (9H, s, C(CH3)3); 13C NMR (CD3OD)
(ppm): 162.1, 158.4 (triazole C-3, C-5), 154.6, 127.4, 126.9 (Ar
79.5, 77.3, 74.2, 71.1 (C-10–C-40), 71.5 (C-50), 35.6 (C(CH3)3), 31.
(C(CH3)3). Anal. Calcd for C17H23N3O4 (333.38): C, 61.25; H, 6.95
N, 12.60. Found: C, 61.20; H, 6.96; N, 12.54.
3.9.15. 3-(2-Naphthyl)-5-(b-D-xylopyranosyl)-1,2,4-triazole (19
From compound 16 (0.14 g, 0.33 mmol) according to Genera
procedure III (Section 3.4). Reaction time: 16 h. Puriﬁed by colum
chromatography (9:1 CHCl3–MeOH) to yield 0.10 g (90%) whit
amorphous solid. Rf: 0.44 (4:1 CHCl3–MeOH); [a]D 22 (c 0.47
MeOH); 1H NMR (CD3OD) d (ppm): 8.36 (1H, s, Ar), 7.93 (1H, d
J = 8.2 Hz, Ar), 7.78–7.69 (3H, m, Ar), 7.38–7.35 (2H, m, Ar), 4.4
(1H, d, J = 9.7 Hz, H-10), 4.00 (1H, dd, J = 11.0, 5.3 Hz, H-50eq), 3.8
(1H, pseudo t, J = 8.9, 8.7 Hz, H-20 or H-30), 3.71 (1H, ddd, J = 9.9
9.5, 5.3 Hz, H-40), 3.51 (1H, pseudo t, J = 8.9, 8.9 Hz, H-20 or H-30
3.37 (1H, pseudo t, J = 11.0, 9.9 Hz, H-50ax); 13C NMR (CD3OD)
(ppm): 160.7, 159.0 (triazole C-3, C-5), 138.8, 135.3, 134.4, 129.7
129.5, 128.7, 128.1, 127.7, 127.2, 124.5 (Ar), 79.5, 77.2, 74.3, 71.
(C-10–C-40), 71.5 (C-50). Anal. Calcd for C17H17N3O4 (327.33): C
62.38; H, 5.23; N, 12.84. Found: C, 62.40; H, 5.19; N, 12.80.
3.9.16. C-(2,3,4-Tri-O-acetyl-b-D-xylopyranosyl)formaldehyde-
tosylhydrazone (21)
To a vigorously stirred solution of pyridine (10 mL), AcO
(6 mL) and water (6 mL) an aqueous suspension of Raney-N
(2.60 g) was added at rt. 2,3,4-Tri-O-acetyl-b-D-xylopyranosyl-cya
nide34 (20, 0.50 g, 1.75 mmol), p-toluenesulfonylhydrazide (0.39
4.43 mmol) and NaH2PO2 (1.30 g, 15 mmol) were then added t
the mixture. When the reaction was complete (TLC, 1:1 EtOAc
hexane) the insoluble materials were ﬁltered off, and washed wit
EtOAc (40 mL). The organic layer of the ﬁltrate was separated
washed with 10% aq HCl solution (3  10 mL), satd aq NaHCO
solution (3  10 mL), water (10 mL) and then dried over MgSO
The solution was concentrated under reduced pressure, the residu
was puriﬁed by column chromatography (1:1 EtOAc–hexane) t
give 0.50 g (63%) white crystals. Mp: 143–147 C; [a]D 14 (
0.98, CHCl3); 1H NMR (CDCl3) d (ppm): 9.20 (1H, s, NH), 7.79 (2H
d, J = 8.1 Hz, Ph), 7.32 (2H, d, J = 8.0 Hz, Ph), 7.00 (1H, d
J = 6.4 Hz, CH), 5.25 (1H, pseudo t, J = 9.5, 9.5 Hz, H-2 or H-3
4.98 (1H, ddd, J = 11.1, 9.6, 5.5 Hz, H-4), 4.92 (1H, pseudo
J = 9.6, 9.6 Hz, H-2 or H-3), 4.10 (1H, dd, J = 11.1, 5.5 Hz, H-5eq
3.90 (1H, dd, J = 9.7, 6.4 Hz, H-1), 3.32 (1H, pseudo t, J = 11.
10.9 Hz, H-5ax), 2.41 (3H, s, CH3), 2.04 (6H, s, 2  CH3) 1.75, (3H
s, CH3); 13C NMR (CDCl3) d (ppm): 170.5, 170.1, 169.9 (C@O
143.9 (CH@N), 135.1, 127.7, 129.5 (Ar), 77.9, 72.4, 69.5, 68.7 (C
1–C-4), 66.3 (C-5), 21.3, 20.5 (2  CH3), 20.1 (CH3). Anal. Calc
for C19H24N2O9S (456.47): C, 49.99; H, 5.30; N, 6.14. Found: C
50.06; H, 5.38; N, 6.19.
3.9.17. 3,4,5-Tri-O-acetyl-2,6-anhydro-1-deoxy-D-xylo-hex-1-
enitol (22)
In a ﬂame-dried three-necked ﬂask NaH (95%, 44 m
1.75 mmol) was added to anhydrous 1,4-dioxane. This stirred sus
pension was heated to reﬂux and a solution of 21 (200 m
0.44 mmol) in anhydrous 1,4-dioxane (13 mL) was added dropwis
during 1.5 h. The reaction was reﬂuxed until the complete disap
pearance of the starting material (TLC, 1:1 EtOAc–hexane). Afte
cooling to rt the insoluble material was ﬁltered off and washe
with anhydrous 1,4-dioxane (10 mL). The ﬁltrate was concentrate
under reduced pressure and the residue was puriﬁed by colum
chromatography (1:1 EtOAc–hexane) to yield 118 mg (99%) whit
amorphous solid. Rf: 0.59 (1:1 EtOAc–hexane); [a]D +8 (c 0.51
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Pl3), 5.11 (1H, pseudo t, J = 7.9, 7.8 Hz, H-4), 5.03 (1H, ddd, J = 8.4,
, 4.8 Hz, H-5), 4.73 (1H, pseudo t, J = 1.5, 1.5 Hz, H-1a), 4.47 (1H,
eudo t, J = 1.5, 1.5 Hz, H-1b), 4.18 (1H, dd, J = 11.1, 4.8 Hz, H-6eq),
5 (1H, dd, J = 11.1, 8.4 Hz, H-6ax), 2.04 (3H, s, CH3), 2.09 (6H, s,
CH3); 13C NMR (CDCl3) d (ppm): 169.7 (2), 169.2 (C@O), 153.5
-2), 95.9 (C-1), 72.1, 68.7 (2) (C-3–C-5), 66.9 (C-6), 20.7
 CH3). Anal. Calcd for C12H16O7 (272.25): C, 52.94; H, 5.92.
und: C, 53.07; H, 5.99.
.18. (10R)-20,30,40-Tri-O -acetyl-10,50-anhydro-D-xylitol-
iro[10,5]-3-phenyl-4,5-dihydro-isoxazole (23)
From compound 22 (100 mg, 0.37 mmol) and benzaldoxime
22 mg, 1.85 mmol) according to General procedure IV (Section
) to yield 105 mg (74%) white amorphous solid. Rf: 0.38 (1:2
OAc–hexane); [a]D +34 (c 0.79, CHCl3); 1H NMR (CDCl3) d
pm): 7.59–7.19 (5H, m, Ar), 5.49 (1H, pseudo t, J = 10.6, 9.2 Hz,
30), 5.29 (1H, d, J = 10.6 Hz, H-20), 5.00 (1H, ddd, J = 10.6, 9.2,
Hz, H-40), 3.92–3.78 (2H, m, H-50ax, H-50eq), 3.25 (2H, br s,
2), 1.98 (9H, m, 3  CH3); 13C NMR (CDCl3) d (ppm): 170.3,
9.9, 169.7 (C@O), 157.7 (C@N), 130.8, 128.8, 128.3, 126.8 (Ar),
7.0 (C-10), 71.1, 69.4, 68.9 (C-20–C-40), 60.2 (C-50), 43.2 (CH2),
.6 (3  CH3). Anal. Calcd for C19H21NO8 (391.38): C, 58.31; H,
1; N, 3.58. Found: C, 58.42; H, 5.54; N, 3.62.
.19. (10R)-20,30,40-Tri-O -acetyl-10,50-anhydro-D-xylitol-
iro[10,5]-3-(4-tert-butylphenyl)-4,5-dihydro-isoxazole (24)
From compound 22 (100 mg, 0.37 mmol) and 4-tert-buty-
nzaldoxime (327 mg, 1.85 mmol) according to General proce-
re IV (Section 3.5) to yield 110 mg (67%) white amorphous
lid. Rf: 0.54 (1:2 EtOAc–hexane); [a]D +29 (c 1.95, CHCl3); 1H
R (CDCl3) d (ppm): 7.59 (2H, d, J = 8.5 Hz, Ar), 7.44 (2H, d,
8.5 Hz, Ar), 5.56 (1H, pseudo t, J = 9.9, 9.8 Hz, H-30), 5.36 (1H,
J = 10.1 Hz, H-20), 5.08 (1H, ddd, J = 10.5, 9.8, 6.2 Hz, H-40), 3.96
H, pseudo t, J = 11.0, 10.9 Hz, H-50ax), 3.73 (1H, dd, J = 11.2,
Hz, H-50eq), 3.31 (2H, s, CH2), 2.06–2.04 (9H, m, 3  CH3),
3 (9H, s, C(CH3)3); 13C NMR (CDCl3) d (ppm): 170.3, 170.0,
9.7 (C@O), 157.5 (C@N), 125.5, 125.8, 126.6, 154.3 (Ar), 106.9
-10), 71.1, 69.4, 68.9 (C-20–C-40), 60.2 (C-50), 43.4 (CH2), 34.9
(CH3)3), 31.1 (C(CH3)3), 20.6 (3  CH3). Anal. Calcd for





From compound 22 (100 mg, 0.37 mmol) and 4-(triﬂuoro-
ethyl)benzaldoxime (327 mg, 1.85 mmol) according to General
ocedure IV (Section 3.5) to yield 96 mg (57%) white amorphous
lid. Rf: 0.49 (1:2 EtOAc–hexane); [a]D +29 (c 2.07, CHCl3); 1H
R (CDCl3) d (ppm): 7.79–7.67 (4H, m, Ar) 5.58 (1H, pseudo t,
9.8, 9.8 Hz, H-30), 5.38 (1H, d, J = 10.1 Hz, H-20), 5.09 (1H, ddd,
10.0, 9.8, 6.5 Hz, H-40), 3.96 (1H, pseudo t, J = 11.1, 11.0 Hz, H-
x), 3.91 (1H, dd, J = 11.2, 6.5 Hz, H-50eq), 3.34 (2H, s, CH2),
7–2.05 (9H, m, 3  CH3); 13C NMR (CDCl3) d (ppm): 170.3,
0.0, 169.7 (C@O), 156.7 (C@N), 131.8, 127.1, 125.8 (Ar), 123.5
, 1J(C,F) = 271.3, CF3), 107.5 (C-10), 70.9, 69.4, 68.8 (C-20–C-40),
.3 (C-50), 42.6 (CH2), 20.6 (3  CH3). Anal. Calcd for C20H20F3NO8




From compound 22 (100 mg, 0.37 mmol) and 1-naphtha-
oxime (316 mg, 1.85 mmol) according to General procedure IV
ection 3.5) to yield 100 mg (60%) white amorphous solid. Rf:
0 (1:2 EtOAc–hexane); [a]D +46 (c 0.81, CHCl3); 1H NMR (CDCl3)ease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (2014ppm): 8.98–7.45 (7H, m, Ar), 5.63 (1H, pseudo t, J = 9.9, 9.8 Hz,
30), 5.42 (1H, d, J = 10.1 Hz, H-20), 5.12 (1H, ddd, J = 10.2, 9.8,
Hz, H-40), 4.04 (1H, pseudo t, J = 11.0, 10.9 Hz, H-50ax), 3.93
H, dd, 1H, J = 11.0, 6.1 Hz, H-50eq), 3.53 (2H, s, CH2), 2.07–2.06
H, m, 3  CH3); 13C NMR (CDCl3) d (ppm): 170.3, 170.0, 169.8
@O), 158.5 (C@N), 133.9–124.7 (Ar), 106.0 (C-10), 71.2, 69.4,
.0 (C-20–C-40), 60.3 (C-50), 46.1 (CH2), 20.7 (3  CH3). Anal. Calcd




From compound 22 (100 mg, 0.37 mmol) and 2-naphtha-
oxime (316 mg, 1.85 mmol) according to General procedure IV
ection 3.5) to yield 71 mg (44%) white amorphous solid. Rf:
2 (1:2 EtOAc–hexane); [a]D +12 (c 0.86, CHCl3); 1H NMR (CDCl3)
ppm): 7.98–7.46 (7H, m, Ar), 5.61 (1H, pseudo t, J = 9.9, 9.8 Hz,
30), 5.41 (1H, d, J = 10.1 Hz, H-20), 5.12 (1H, ddd, J = 10.3,
Hz, H-40), 4.00 (1H, pseudo t, J = 11.0, 10.9 Hz, H-50ax), 3.90
H, dd, J = 11.1, 6.1 Hz, H-50eq), 3.45 (2H, br s, CH2), 2.06–2.05
H, m, 3  CH3); 13C NMR (CDCl3) d (ppm): 170.3, 169.9, 169.7
@O), 157.8 (C@N), 134.2–123.0 (Ar), 107.1 (C-10), 71.1, 69.4,
.9 (C-20–C-40), 60.2 (C-50), 43.2 (CH2), 20.6 (3  CH3). Anal. Calcd




From compound 22 (100 mg, 0.37 mmol) and benzothiazole-2-
rbaldoxime (329 mg, 1.85 mmol) according to General procedure
(Section 3.5) to yield 117 mg (71%) yellow amorphous solid. Rf:
0 (1:2 EtOAc–hexane); [a]D +1 (c 1.83, CHCl3); 1H NMR (CDCl3) d
pm): 8.05–7.45 (4H, m, Ar), 5.59 (1H, pseudo t, J = 9.8, 9.8 Hz, H-
, 5.43 (1H, d, J = 10.1 Hz, H-20), 5.17–5.09 (1H, m, H-40), 3.98–
5 (2H, m, H-50ax, H-50eq), 3.63 (1H, d, J = 18.4 Hz, CH2a), 3.56
H, d, J = 18.5 Hz, CH2b), 2.07–2.06, (9H, m, 3  CH3); 13C NMR
DCl3) d (ppm): 169.8, 169.7, 169.6 (C@O), 156.4, 155.5, 152.7
@N, CAN), 126.7, 126.5, 123.7, 121.7 (Ar), 108.3, (C-10), 68.5,
.1, 70.8 (C-20–C-40), 60.4 (C-50), 42.6 (CH2), 20.4 (3  CH3). Anal.
lcd for C20H20N2O8S (448.45): C, 53.57; H, 4.50; N, 6.25. Found:
53.63; H, 4.57; N, 6.31.
.24. (10R )-10,50-Anhydro-D-xylitol-spiro[10,5]-3-phenyl-4,5-
hydro-isoxazole (29)
From compound 23 (100 mg, 0.26 mmol) according to General
ocedure I (Section 3.2). The crude product was crystallized from
OH to yield 61 mg (90%) white crystals. Mp: 180–183 C; [a]D
0 (c 0.90, MeOH); 1H NMR (CD3OD) d (ppm): 7.69–7.67 (2H, m,
), 7.44–7.43 (3H, m, Ph), 3.76–3.56 (6H, m, H-20, H-30, H-40, H-
x, H-50eq, CH2a), 3.25 (1H, d, J = 17.7 Hz, CH2b); 13C NMR (CD3-
) d (ppm): 159.8 (C@N), 131.7, 130.3, 130.0, 127.8 (Ar), 110.9
-10), 76.4, 73.0, 71.2 (C-20–C-40), 64.9 (C-50), 44.2 (CH2). Anal.
lcd for C13H15NO5 (265.26): C, 58.86; H, 5.70; N, 5.28. Found:
58.92; H, 5.59; N, 5.21.
.25. (10R )-10,50-Anhydro-D-xylitol-spiro[10,5]-3-(4-tert-
tylphenyl)-4,5-dihydro-isoxazole (30)
From compound 24 (100 mg, 0.23 mmol) according to General
ocedure I (Section 3.2). The crude product was crystallized from
OH to yield 69 mg (98%) white crystals. Mp: 238–242 C; [a]D
3 (c 2.50, DMSO); 1H NMR (DMSO-d6) d (ppm): 7.59 (2H, d,
7.9 Hz, Ar), 7.46 (2H, d, J = 8.0 Hz, Ar), 5.33 (1H, br s, OH), 5.08
H, m, 2  OH), 3.58 (1H, d, J = 17.8 Hz, CH2a), 3.53–3.36 (5H,
, H-20, H-30, H-40, H-50ax, H-50eq), 3.18 (1H, d, J = 17.7 Hz,
2b), 1.28 (9H, s, C(CH3)3); 13C NMR (DMSO-d6) d (ppm): 157.0
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10 June 2014(C-20–C-40), 63.7 (C-50), 42.7 (CH2), 34.5 (C(CH3)3), 30.8 (C(CH3)3
Anal. Calcd for C17H23NO5 (321.37): C, 63.54; H, 7.21; N, 4.36
Found: C, 63.61; H, 7.10; N, 4.42.
3.9.26. (10R )-10,50-Anhydro-D-xylitol-spiro[10,5]-3-(4-
triﬂuoromethylphenyl)-4,5-dihydro-isoxazole (31)
From compound 25 (100 mg, 0.23 mmol) according to Genera
procedure I (Section 3.2). The crude product was crystallized from
EtOH to yield 66 mg (91%) white crystals. Mp: 197–198 C; [a]
+47 (c 0.36, MeOH); 1H NMR (CD3OD) d (ppm): 7.79–7.62 (4H, m
Ar), 3.71–3.49 (7H, m, H-20, H-30, H-40, H-50ax, H-50eq, CH2);13
NMR (CD3OD) d (ppm): 158.4 (C@N), 134.2, 128.3, 126.7 (Ar
111.5 (C-10), 76.3, 73.1, 71.1 (C-20–C-40), 65.0 (C-50), 43.8 (CH2
Anal. Calcd for C14H14F3NO5 (333.26): C, 50.46; H, 4.23; N, 4.20
Found: C, 50.39; H, 4.33; N, 4.26.
3.9.27. (10R )-10,50-Anhydro-D-xylitol-spiro[10,5]-3-(1-naphthyl)
4,5-dihydro-isoxazole (32)
From compound 26 (100 mg, 0.23 mmol) according to Genera
procedure I (Section 3.2). The crude product was crystallized from
EtOH to yield 57 mg (79%) white crystals. Mp: 179–180 C; [a]
+66 (c 0.95, MeOH); 1H NMR (CD3OD) d (ppm): 8.73–8.71 (1H, m
Ar), 7.81–7.79 (2H, m, Ar), 7.48–7.36 (4H, m, Ar), 3.82 (1H, d
J = 17.6 Hz, CH2a), 3.76–3.56 (6H, m, H-20, H-30, H-40, H-50ax, H
50eq, CH2b); 13C NMR (CD3OD) d (ppm): 160.3 (C@N), 135.4
126.1 (Ar), 109.9 (C-10), 76.5, 73.0, 71.3 (C-20–C-40), 65.0 (C-50
47.2 (CH2). Anal. Calcd for C17H17NO5 (315.32): C, 64.75; H, 5.43
N, 4.44. Found: C, 64.89; H, 5.37; N, 4.39.
3.9.28. (10R )-10,50-Anhydro-D-xylitol-spiro[10,5]-3-(2-naphthyl)
4,5-dihydro-isoxazole (33)
From compound 27 (100 mg, 0.23 mmol) according to Genera
procedure I (Section 3.2). The crude product was crystallized from
EtOH to yield 61 mg (85%) white crystals. Mp: 191–194 C; [a]
+44 (c 1.07, DMSO); 1H NMR (DMSO-d6) d (ppm): 8.14–7.58 (7H
m, Ar), 5.41 (1H, br s, OH), 5.14–5.11 (2H, m, 2  OH), 3.73 (1H
d, J = 17.6 Hz, CH2a), 3.56–3.38 (6H, m, H-20, H-30, H-40, H-50ax, H
50eq, CH2b); 13C NMR (DMSO-d6) d (ppm): 157.4 (C@N), 133.5
122.8 (Ar), 109.9 (C-10), 74.4, 71.5, 69.5 (C-20–C-40), 63.8 (C-50
42.6 (CH2). Anal. Calcd for C17H17NO5 (315.32): C, 64.75; H, 5.43
N, 4.44. Found: C, 64.89; H, 5.42; N, 4.36.
3.9.29. (10R )-10,50-Anhydro-D-xylitol-spiro[10,5]-3-(2-
benzothiazolyl)-4,5-dihydro-isoxazole (34)
From compound 28 (100 mg, 0.23 mmol) according to Genera
procedure I (Section 3.2). The crude product was crystallized from
EtOH to yield 47 mg (65%) white crystals. Mp: 225–230 C; [a]
+47 (c 1.15, MeOH); 1H NMR (CD3OD) d (ppm): 7.88–7.73 (2H
m, Ar), 7.46–7.33 (2H, m, Ar), 3.79–3.67 (7H, m, H-20, H-30, H-4
H-50ax, H-50eq, CH2);13C NMR (CD3OD) d (ppm): 158.5, 156.7
153.0 (C@N, CAN), 135.3, 128.3, 128.0, 124.0, 123.0 (Ar), 112.
(C-10), 75.7, 72.5, 70.4 (C-20–C-40), 64.9 (C-50), 43.3 (CH2). Ana
Calcd for C14H14N2O5S (322.33): C, 52.17; H, 4.38; N, 8.69. Found
C, 52.25; H, 4.45; N, 8.75.
3.9.30. 2,3,4-Tri-O-acetyl-1-S-(Z)-benzhydroximoyl-1-thio-b-D-
xylopyranose (36)
A: From compound 35 (1.61 g, 5.51 mmol) and N-hydroxy-ben
zenecarboximidoyl chloride (1.29 g, 8.27 mmol) according to Gen
eral procedure V (Section 3.6). Yield: 1.43 g (63%).
B: From compound 35 (1.00 g, 3.42 mmol) and benzaldoxim
(0.62 g, 5.14 mmol) according to General procedure VI (Sectio
3.7). Yield: 0.88 g (62%), white crystals. Mp: 165–168 C; [a]D +1
(c 0.46, CHCl3); 1H NMR (CDCl3) d (ppm): 9.10 (1H, s, OH), 7.52
7.40 (5H, m, Ar), 5.02–4.97 (2H, m, H-2, H-3), 4.86 (1H, ddd
J = 8.7, 8.3, 4.9 Hz, H-4), 4.60 (1H, strongly coupled m, H-1), 4.0Please cite this article in press as: Somsák, L.; et al. Carbohydr. Res. ((1H, dd, J = 11.8, 4.9 Hz, H-5eq), 2.88 (1H, dd, J = 11.8, 8.7 Hz, H
5ax), 2.04, 2.03, 1.98 (3  3H, 3 s, CH3); 13C NMR (CDCl3)
(ppm): 169.9, 169.7, 169.3 (C@O), 152.5 (C@N), 132.3, 130.
128.9, 128.5 (Ar), 81.8 (C-1), 71.7, 69.8, 68.1 (C-2–C-4), 64.9 (C
5), 20.6 (3  CH3). Anal. Calcd for C18H21NO8S (411.43): C, 52.55
H, 5.14; N, 3.40. Found: C, 52.39; H, 5.17; N, 3.49.
3.9.31. 2,3,4-Tri-O-acetyl-1-S-(Z)-1-naphthhydroximoyl-1-thio
b-D-xylopyranose (37)
A: From compound 35 (0.93 g, 3.17 mmol) and N-hydroxy-1
naphthalenecarboximidoyl chloride (0.98 g, 4.75 mmol) accordin
to General procedure V (Section 3.6). Yield: 1.22 g (83%).
B: From compound 35 (1.50 g, 5.14 mmol) and 1-naphtha
ldoxime (1.32 g, 7.71 mmol) according to General procedure V
(Section 3.7). Yield: 1.62 g (68%), white amorphous solid. Rf: 0.5
(1:1 EtOAc–hexane); [a]D +22 (c 0.52, CHCl3); 1H NMR (CDCl3)
(ppm): 9.24 (1H, br s, OH), 7.98–7.51 (7H, m, Ar), 4.91 (1H, pseud
t, J = 8.6, 8.4 Hz, H-2 or H-3), 4.78–4.69 (2H, m, H-2 or H-3, H-4
4.03 (1H, d, J = 8.6 Hz, H-1), 3.66 (1H, dd, J = 11.9, 4.6 Hz, H-5eq
2.23 (1H, dd, J = 11.9, 8.7 Hz, H-5ax), 1.97, 1.94, 1.89 (3  3H, 3
CH3); 13C NMR (CDCl3) d (ppm): 169.9, 169.6, 169.1 (C@O), 152.
(C@N), 133.2, 131.8, 130.3, 128.7, 128.2, 126.9, 126.6, 125.1
124.7 (Ar), 81.4 (C-1), 71.9, 69.2, 68.1 (C-2–C-4), 64.7 (C-5), 20.
(3  CH3). Anal. Calcd for C22H23NO8S (461.48): C, 57.26; H, 5.02
N, 3.04. Found: C, 57.32; H, 5.14; N, 2.93.
3.9.32. 2,3,4-Tri-O-acetyl-1-S-(Z)-2-naphthhydroximoyl-1-thio
b-D-xylopyranose (38)
A: From compound 35 (0.86 g, 2.96 mmol) and N-hydroxy-2
naphthalenecarboximidoyl chloride (0.91 g, 4.43 mmol) accordin
to General procedure V (Section 3.6). Yield: 1.23 g (91%).
B: From compound 35 (1.71 g, 5.84 mmol) 2-naphthaldoxim
(1.50 g, 8.76 mmol) according to General procedure VI (Sectio
3.7). Yield: 2.10 g (77%), white crystals. Mp: 169–172 C; [a]D +1
(c 0.50, CHCl3); 1H NMR (CDCl3) d (ppm): 9.09 (1H, s, OH), 8.06
7.52 (7H, m, Ar), 5.04, 4.97 (2  1H, 2 pseudo t, J = 8.0, 8.0 Hz i
each, H-2, H-3), 4.87 (1H, ddd, J = 8.6, 8.0, 4.9 Hz, H-4), 4.70 (1H
d, J = 8.0 Hz, H-1), 4.08 (1H, dd, J = 11.7, 4.9 Hz, H-5eq), 2.88 (1H
dd, J = 11.7, 8.6 Hz, H-5ax), 2.05, 2.03, 1.95 (3  3H, 3 s, CH3); 13
NMR (CDCl3) d (ppm): 169.8, 169.7, 169.3 (C@O), 152.4 (C@N
133.8, 132.7, 129.8, 129.0, 128.5, 128.2, 127.7, 127.3, 126.7, 125.
(Ar), 81.8 (C-1), 71.5, 69.8, 68.1 (C-2–C-4), 64.8 (C-5), 20.
(3  CH3). Anal. Calcd for C22H23NO8S (461.48): C, 57.26; H, 5.02
N, 3.04. Found: C, 57.34; H, 4.89; N, 3.10.
3.9.33. 1-S-(Z)-Benzhydroximoyl-1-thio-b-D-xylopyranose (39)
From compound 36 (0.20 g, 0.49 mmol) according to Genera
procedure I (Section 3.2). Puriﬁed by column chromatograph
(9:1 CHCl3–MeOH) to yield 0.12 g (89%) white solid. Mp: 174
178 C; [a]D 5 (c 0.50, DMSO); 1H NMR (DMSO-d6) d (ppm
7.44–7.43 (5H, m, Ar), 5.41, 5.12, 4.90 (3  1H, 3 d, OH), 4.1
(1H, d, J = 9.2 Hz, H-1), 3.57 (1H, dd, J = 11.2, 4.9 Hz, H-5eq), 3.2
(1H, m, H-4), 3.07, 2.91 (2  1H, 2 m, H-2, H-3), 2.38 (1H, pseud
t, J = 11.2, 9.9 Hz, H-5ax); 13C NMR (DMSO-d6) d (ppm): 151.
(C@N), 133.6, 129.0, 128.5, 128.0 (Ar), 84.2 (C-1), 77.6, 72.5, 69.
(C-2–C-4), 68.9 (C-5). Anal. Calcd for C12H15NO5S (285.32): C
50.52; H, 5.30; N, 4.91. Found: 50.46; H, 5.52; N, 4.87.
3.9.34. 1-S-(Z)-1-Naphthhydroximoyl-1-thio-b-D-xylopyranose
(40)
From compound 37 (0.20 g, 0.43 mmol) according to Genera
procedure I (Section 3.2). Puriﬁed by column chromatograph
(9:1 CHCl3–MeOH) to yield 0.14 g (98%) brownish solid. Mp
198–202 C; [a]D +16 (c 0.53, DMSO); 1H NMR (CD3OD) d (ppm
8.04–7.51 (7H, m, Ar), 3.72 (1H, d, J = 9.7 Hz, H-1), 3.31–3.25 (2H
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Pl3 (1H, pseudo t, J = 8.7, 8.3 Hz, H-2 or H-3), 1.91 (1H, strongly
upled m, H-5ax); 13C NMR (CD3OD) d (ppm): 154.1 (C@N),
4.7, 133.5, 131.3, 130.9, 129.5, 129.1, 127.7, 127.4, 126.8, 125.8
r), 85.6 (C-1), 79.2, 73.5, 70.6 (C-2–C-4), 69.9 (C-5). Anal. Calcd
r C16H17NO5S (335.37): C, 57.30; H, 5.11; N, 4.18. Found: C,
.34; H, 5.26; N, 4.09.
.35. 1-S-(Z)-2-Naphthhydroximoyl-1-thio-b-D-xylopyranose
1)
From compound 38 (0.20 g, 0.43 mmol) according to General
ocedure I (Section 3.2). Puriﬁed by column chromatography
:1 CHCl3–MeOH) to yield 0.13 g (92%) pale yellow solid. Mp:
5–188 C; [a]D +1 (c 0.46, DMSO); 1H NMR (CD3OD) d (ppm):
5–7.51 (7H, m, Ar), 4.26 (1H, d, J = 9.7 Hz, H-1), 3.68 (1H, dd,
11.7, 5.3 Hz, H-5eq), 3.41 (1H, ddd, J = 10.2, 8.7, 5.3 Hz, H-4),
9 (1H, pseudo t, J = 9.7, 8.7 Hz, H-2 or H-3), 3.04 (1H, t,
8.7 Hz, H-2 or H-3), 2.43 (1H, pseudo t, J = 11.2, 10.2 Hz, H-
x); 13C NMR (CD3OD) d (ppm): 154.1 (C@N), 135.0, 134.1,
2.3, 130.0, 129.4, 128.8, 128.1, 127.7, 127.3 (Ar), 85.9 (C-1),
.2, 74.1, 70.6 (C-2 – C-4), 70.3 (C-5). Anal. Calcd for C16H17NO5S
35.37): C, 57.30; H, 5.11; N, 4.18. Found: C, 57.40; H, 5.03; N,
7.
.36. (10R)-20,30,40-Tri-O -acetyl-10,50-anhydro-D-xylitol-
iro[10,5]-3-phenyl-1,4,2-oxathiazole (42) and (10S)-20,30,40-tri-
acetyl-10,50-anhydro-D-xylitol-spiro[10,5]-3-phenyl-1,4,2-
athiazole (45)
From compound 36 (1.00 g, 2.43 mmol) according to General
ocedure VII (Section 3.8). Puriﬁed by column chromatography
:4 EtOAc–hexane) to give 45 as the ﬁrst and 42 as the second
ction.
Compound 42: Yield: 310 mg (31%), white solid. Mp: 158–
1 C; [a]D +178 (c 1.68, CHCl3); 1H NMR (CDCl3) d (ppm): 7.70–
1 (7H, m, Ar), 5.52 (1H, d, J = 8.7 Hz, H-20), 5.13 (1H, pseudo t,
8.7, 8.3 Hz, H-30), 5.07 (1H, ddd, J = 8.7, 8.3, 4.9 Hz, H-40), 4.19
H, dd, J = 12.1, 4.9 Hz, H-50eq), 3.79 (1H, dd, J = 12.1, 8.7 Hz, H-
x), 2.08 (2), 2.07 (9H, 2 s, CH3); 13C NMR (CDCl3) d (ppm):
9.4 (2), 168.4 (C@O), 155.5 (C@N), 131.4, 128.8, 127.7, 127.1
r), 126.6 (C-10), 71.7, 68.3, 67.3 (C-20–C-40), 61.1 (C-50), 20.4
 CH3). Anal. Calcd for C18H19NO8S (409.41): C, 52.81; H, 4.68;
3.42. Found: C, 52.96; H, 4.64; N, 3.33.
Compound 45: Yield: 71 mg (7%), pale yellow solid. Mp: 122–
4 C; [a]D +78 (c 0.26, CHCl3); 1H NMR (CDCl3) d (ppm): 7.67–
1 (5H, m, Ar), 5.62 (1H, pseudo t, J = 9.8, 9.2 Hz, H-30), 5.56
H, d, J = 9.8 Hz, H-20), 5.12 (1H, ddd, J = 9.7, 9.2, 6.8 Hz, H-40),
4 (1H, pseudo t, J = 11.2, 9.7 Hz, H-50ax), 4.00 (1H, dd, J = 11.2,
Hz, H-50eq), 2.08, 2.07, 2.06 (3  3H, 3 s, CH3); 13C NMR (CDCl3)
ppm): 169.7, 169.4 (2) (C@O), 156.2 (C@N), 131.5, 128.9, 127.9,
7.0 (Ar), 122.6 (C-10), 70.4, 68.4, 68.1 (C-20–C-40), 61.2 (C-50), 20.5
 CH3). Anal. Calcd for C18H19NO8S (409.41): C, 52.81; H, 4.68;
3.45. Found: C, 52.63; H, 4.75; N, 3.57.
.37. (10R)-20,30,40-Tri-O -acetyl-10,50-anhydro-D-xylitol-
iro[10,5]-3-(1-naphthyl)-1,4,2-oxathiazole (43) and (10S)-
30,40-tri-O -acetyl-10,50-anhydro-D-xylitol-spiro[10,5]-3-(1-
phthyl)-1,4,2-oxathiazole (46)
From compound 37 (1.00 g, 2.17 mmol) according to General
ocedure VII (Section 3.8). Puriﬁed by column chromatography
:4 EtOAc–hexane) to give 46 as the ﬁrst and 43 as the second
ction.
Compound 43: Yield: 233 mg (23%), pale yellow solid. Mp: 153–
6 C; [a]D +151 (c 1.18, CHCl3); 1H NMR (CDCl3) d (ppm): 8.61–
7 (7H, m, Ar), 5.58 (1H, d, J = 8.3 Hz, H-20), 5.15 (1H, pseudo t,
8.3, 7.8 Hz, H-30), 5.10 (1H, ddd, J = 8.7, 7.8, 3.9 Hz, H-40), 4.28
H, dd, J = 11.2, 3.9 Hz, H-50eq), 3.85 (1H, dd, J = 11.2, 8.7 Hz,
















ease cite this article in press as: Somsák, L.; et al. Carbohydr. Res. (2014(ppm): 169.5 (2), 168.5 (C@O), 154.9 (C@N), 133.6, 131.9,
0.2, 129.5, 128.4, 127.6, 126.6 (Ar), 125.8 (C-10), 125.5, 124.7,
3.7 (Ar), 71.6, 68.5, 67.3 (C-20–C-40), 61.2 (C-50), 20.5 (3  CH3).
al. Calcd for C22H21NO8S (459.47): C, 57.51; H, 4.61; N, 3.05.
und: C, 57.68; H, 4.56; N, 3.13.
Compound 46: Yield: 66 mg (7%), pale yellow solid. Mp: 145–
8 C; [a]D +73 (c 0.23, CHCl3); 1H NMR (CDCl3) d ppm: 8.65–
6 (7H, m, Ar), 5.68 (1H, pseudo t, J = 9.7, 9.2 Hz, H-30), 5.59
H, d, J = 9.7 Hz, H-20), 5.14 (1H, ddd, J = 10.2, 9.2, 6.3 Hz, H-40),
1 (1H, dd, J = 11.2, 10.2 Hz, H-50ax), 4.06 (1H, dd, J = 11.2,
Hz, H-50eq), 2.13, 2.08, 2.07 (3  3H, 3 s, CH3); 13C NMR (CDCl3)
(ppm): 169.8, 169.5, 169.4 (C@O), 155.6 (C@N), 133.7, 132.0,
0.3, 129.8, 128.5, 127.8, 126.7, 125.6, 124.8, 123.6 (Ar), 121.9
-10), 70.5, 68.4, 68.2 (C-20–C-40), 61.3 (C-50), 20.6 (3  CH3). Anal.
lcd for C22H21NO8S (459.47): C, 57.51; H, 4.61; N, 3.05. Found: C,
.62; H, 4.70; N, 2.94.
.38. (10R)-20,30,40-Tri-O -acetyl-10,50-anhydro-D-xylitol-
iro[10,5]-3-(2-naphthyl)-1,4,2-oxathiazole (44) and (10S)-
30,40-tri-O -acetyl-10,50-anhydro-D-xylitol-spiro[10,5]-3-(2-
phthyl)-1,4,2-oxathiazole (47)
From compound 38 (1.00 g, 2.17 mmol) according to General
ocedure VII (Section 3.8). Puriﬁed by column chromatography
:4 EtOAc–hexane) to give 47 as the ﬁrst and 44 as the second
ction.
Compound 44: Yield: 315 mg (32%), white powder. Mp:181–
4 C, [a]D +182 (c 0.85, CHCl3); 1H NMR (360 MHz, CDCl3) d
pm): 8.04–7.53 (7H, m, Ar), 5.56 (1H, d, J = 8.7 Hz, H-20), 5.17
H, pseudo t, J = 8.7, 8.3 Hz, H-30), 5.11 (1H, ddd, J = 8.7, 8.3,
Hz, H-40), 4.22 (1H, dd, J = 12.1, 4.9 Hz, H-50eq), 3.83 (1H, dd,
12.1, 8.7 Hz, H-50ax), 2.09, 2.08 (9H, 2 s, CH3); 13C NMR (CDCl3)
pm: 169.5 (2), 168.4 (C@O), 155.7 (C@N), 134.4, 132.6, 129.0,
8.6, 128.4, 127.7, 126.9 (Ar), 126.7 (C-10), 124.6, 123.5 (Ar),
.8, 68.4, 67.3 (C-20–C-40), 61.2 (C-50), 20.5 (3  CH3). Anal. Calcd
r C22H21NO8S (459.47): C, 57.51; H, 4.61; N, 3.05. Found: C,
.57; H, 4.49; N, 3.01.
Compound 47: Yield: 120 mg (12%), pale yellow solid, Mp: 140–
3 C, [a]D +61 (c 0.28, CHCl3); 1H NMR (360 MHz, CDCl3) d ppm:
8–7.50 (7H, m, Ar), 5.66 (1H, pseudo t, J = 9.7, 8.7 Hz, H-30), 5.60
H, d, J = 9.7 Hz, H-20), 5.15 (1H, ddd, J = 9.7, 8.7, 6.8 Hz, H-40), 4.07
H, dd, J = 11.2, 9.7 Hz, H-50ax), 4.02 (1H, dd, J = 11.2, 6.8 Hz, H-
q), 2.09, 2.07 (2) (9H, 2 s, CH3); 13C NMR (CDCl3) d (ppm):
9.7, 169.4 (2) (C@O), 156.2 (C@N), 134.5, 132.6, 129.2, 128.7,
8.5, 127.8, 127.0, 124.5, 123.4 (Ar), 122.6 (C-10), 70.4, 68.3,
.1 (C-20–C-40), 61.2 (C-50), 20.5 (3  CH3). Anal. Calcd for C22H21-
8S (459.47): C, 57.51; H, 4.61; N, 3.05. Found: C, 57.37; H, 4.65;
3.21.
0 0 0 0.39. (1 S )-1 ,5 -Anhydro-D-xylitol-spiro[1 ,5]-3-phenyl-1,4,2-
athiazole (48)
990From compound 45 (50 mg, 0.12 mmol) according to General
ocedure I (Section 3.2). Reaction time: 10 min. Puriﬁed by col-
n chromatography (4:1 CHCl3–MeOH) to yield 24 mg (70%)
ite crystals. Mp: 123–126 C; [a]D +64 (c 0.25, CHCl3); 1H NMR
MSO-d6) d (ppm): 7.66–7.49 (5H, m, Ar), 5.76, 5.42, 5.24
 1H, 3 d, OH), 3.78–3.68 (2H, m, H-20, H-50a), 3.59 (1H, m, H-
), 3.52–3.40 (2H, m, H-30, H-40); 13C NMR (DMSO-d6) d (ppm):
5.3 (C@N), 131.4, 129.2, 127.3, 126.6 (Ar), 125.1 (C-10), 73.9,
.2, 68.6 (C-20–C-40), 64.7 (C-50). Anal. Calcd for C12H13NO5S




From compound 47 (80 mg, 0.17 mmol) according to General
ocedure I (Section 3.2). Reaction time: 10 min. Puriﬁed by
), http://dx.doi.org/10.1016/j.carres.2014.05.020
column chromatography (4:1 CHCl3–MeOH) to yield 35 mg (60%)
white solid. Mp: 175–178 C, [a]D +25 (c 0.25, CHCl3); 1H NMR
(DMSO-d6) d (ppm): 8.14–7.57 (7H, m, Ar), 5.80, 5.47, 5.28
(3  1H, 3 d, OH), 3.81 (1H, m, H-20), 3.74 (1H, m, H-50a), 3.64
(1H, m, H-50b), 3.58–3.46 (2H, m, H-30, H-40); 13C NMR (DMSO-
1010 d6) d (ppm): 155.7 (C@N), 134.2, 132.8, 129.0, 128.7, 128.1,
127.9, 127.4, 126.8, 125.2, 123.3 (Ar), 123.5 (C-10), 73.9, 71.4,
68.8 (C-20–C-40), 64.9 (C-50). Anal. Calcd for C16H15NO5S (333.07):
C, 57.65; H, 4.54; N, 4.20. Found: C, 57.73; H, 4.61; N, 4.06.
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